Experts Hampered In Depakote Birth Defect Trial, Mom Says

Law360, New York (December 1, 2016, 8:26 PM EST) -- A mother alleging her child's birth defects were caused by Abbott Laboratories Inc.'s anti-seizure drug Depakote pressed the Sixth Circuit for a new trial, saying Thursday the lower court wrongly limited crucial testimony from three doctors who have called the medication's warning labels inadequate.

The lower court found that the doctors could only opine on the accuracy of the labels and could not offer opinions on the adequacy of the labels, Janet Abaray of Burg Simpson Eldredge Hersh & Jardine PC told the appellate panel. She...
To view the full article, register now.

Related

Sections

Case Information

Case Title

Pamela Rheinfrank v. Abbott Laboratories, Inc., et al


Case Number

16-3347

Court

Appellate - 6th Circuit

Nature of Suit

4365 P.I.: Product Liability

Date Filed

April 8, 2016

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.